# Chronic Kidney Disease Development in Cancer Treatment and Survival

> **NIH NIH R21** · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · 2021 · $389,545

## Abstract

Project Summary/Abstract
Chronic kidney disease (CKD), defined as Stages 3-5, including end stage renal disease
(ESRD)) at the time of cancer diagnosis is believed to influence cancer outcomes, but the base
of evidence for such effects is limited. We seek in this proposal to extend the understanding of
CKD as a risk factor for cancer mortality, and to quantify the development of incident CKD in
patients treated with specific potentially nephrotoxic cancer regimens. In particular, cisplatin,
carboplatin, capecitabine, irinotecan, and etoposide are components of standard cancer
treatment protocols, and treated individuals have had an increased CKD risk in some cancers,
but the risk following standard lung or colorectal cancer treatment is unknown. Approximately
15% of adults in the United States are estimated to be affected with CKD as of 2020. There is a
pressing need to understand the risks of CKD incidence, progression and mortality in the setting
of cancer treatment. We will utilize a large, population-based dataset, that of the Surveillance
Epidemiology End Results (SEER) program of the National Cancer Institute, linked to Medicare
(SEER-Medicare), to address question of import to prognosis in both CKD and cancer.
Surprisingly little of the existing literature concerns long-term follow-up. Such evidence could be
crucial to reduce nephrotoxicity, acute kidney injury, and ensure that dose-limiting side effects of
antineoplastic agents do not prevent effective therapy of the cancer of interest. We will analyze
claims data to evaluate whether those with CKD are at greater risk of cancer or CKD-related
mortality after cancer treatment, and whether particular therapies might increase the risk of CKD
incidence. These analyses should greatly heighten awareness of CKD at diagnosis and that
which develops during therapy, leading to additional monitoring, personalized therapy, and
potential survival benefits for patients with cancer and CKD alike.

## Key facts

- **NIH application ID:** 10289430
- **Project number:** 1R21CA264805-01
- **Recipient organization:** UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
- **Principal Investigator:** Deirdre Hill
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $389,545
- **Award type:** 1
- **Project period:** 2021-09-16 → 2023-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10289430

## Citation

> US National Institutes of Health, RePORTER application 10289430, Chronic Kidney Disease Development in Cancer Treatment and Survival (1R21CA264805-01). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10289430. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*